Nathan J. Dowden Sells 847 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden sold 847 shares of Entrada Therapeutics stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $16.00, for a total value of $13,552.00. Following the sale, the chief operating officer now owns 125,149 shares of the company’s stock, valued at approximately $2,002,384. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Entrada Therapeutics Price Performance

TRDA opened at $16.00 on Wednesday. The stock has a market capitalization of $595.20 million, a price-to-earnings ratio of 24.14 and a beta of -0.24. The business has a 50-day moving average of $15.70 and a two-hundred day moving average of $14.89. Entrada Therapeutics, Inc. has a 12 month low of $10.75 and a 12 month high of $18.17.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $0.65 by $0.90. The company had revenue of $94.69 million during the quarter, compared to analysts’ expectations of $55.00 million. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. Equities research analysts anticipate that Entrada Therapeutics, Inc. will post 0.68 earnings per share for the current year.

Analyst Ratings Changes

TRDA has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 14th. Oppenheimer restated an “outperform” rating and issued a $25.00 price target on shares of Entrada Therapeutics in a report on Monday, August 26th.

Hedge Funds Weigh In On Entrada Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in shares of Entrada Therapeutics in the 1st quarter valued at about $79,000. Vanguard Group Inc. lifted its stake in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after purchasing an additional 13,742 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after purchasing an additional 11,965 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after purchasing an additional 14,838 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Entrada Therapeutics by 25.3% in the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after purchasing an additional 7,452 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.